{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:51:34Z","timestamp":1782478294266,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,23]],"date-time":"2027-06-23T00:00:00Z","timestamp":1813708800000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["BX005921"],"award-info":[{"award-number":["BX005921"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AAR076766"],"award-info":[{"award-number":["R01 AAR076766"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jid.2025.12.020","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:08:07Z","timestamp":1768460887000},"page":"1827-1836.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in dermatomyositis"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-0212","authenticated-orcid":false,"given":"DeAnna","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-5617","authenticated-orcid":false,"given":"Thomas","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-9469","authenticated-orcid":false,"given":"Nilesh","family":"Kodali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-2850","authenticated-orcid":false,"given":"Muhammad M.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-5185","authenticated-orcid":false,"given":"Madison","family":"Grinnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0588-7002","authenticated-orcid":false,"given":"Rohan","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-7323","authenticated-orcid":false,"given":"Emily","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8035-2953","authenticated-orcid":false,"given":"Joshua","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-7813","authenticated-orcid":false,"given":"Julianne","family":"Kleitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1697-1659","authenticated-orcid":false,"given":"Caroline J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.12.020_bib1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study","volume":"141","author":"Ang","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108355","article-title":"Herbal supplement Spirulina stimulates inflammatory cytokine production in patients with dermatomyositis in vitro","volume":"26","author":"Bax","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jid.2025.12.020_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008688","article-title":"Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors","volume":"5","author":"Cencioni","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2025.12.020_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/fcp.12716","article-title":"Targeting cannabinoid receptor 2 (CB2) limits collagen production-An in vitro study in a primary culture of human fibroblasts","volume":"36","author":"Correia-S\u00e1","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jid.2025.12.020_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","article-title":"Fibroblasts as immune regulators in infection, inflammation and cancer","volume":"21","author":"Davidson","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2025.12.020_bib6","first-page":"149","article-title":"Chapter 13. Physiopathology and use of cannabinoids for fibrotic diseases","author":"del R\u00edo","year":"2023"},{"key":"10.1016\/j.jid.2025.12.020_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual PPAR\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"Garc\u00eda-Mart\u00edn","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jid.2025.12.020_bib9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cyto.b.20485","article-title":"Considerations for the control of background fluorescence in clinical flow cytometry","volume":"76","author":"Hulspas","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jid.2025.12.020_bib12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2169\/internalmedicine.47.0967","article-title":"Flow cytometric analysis of lymphocyte subpopulations and Th1\/Th2 balance in patients with polymyositis and dermatomyositis","volume":"47","author":"Ishii","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.jid.2025.12.020_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.31887\/DCNS.2007.9.4\/nkogan","article-title":"Cannabinoids in health and disease","volume":"9","author":"Kogan","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.jid.2025.12.020_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s13075-014-0437-9","article-title":"Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints","volume":"16","author":"Krustev","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2025.12.020_bib16","article-title":"Crosstalk between fibroblasts and T cells in immune networks","volume":"13","author":"Lee","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2025.12.020_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0167-5699(95)80068-9","article-title":"Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases","volume":"16","author":"Liblau","year":"1995","journal-title":"Immunol Today"},{"key":"10.1016\/j.jid.2025.12.020_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13075-021-02665-x","article-title":"Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM","volume":"24","author":"Maddukuri","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2025.12.020_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0952-7915(96)80013-6","article-title":"Manipulation of the Th1\/Th2 balance in autoimmune disease","volume":"8","author":"Nicholson","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jid.2025.12.020_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41584-021-00665-4","article-title":"Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases","volume":"17","author":"Noack","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2025.12.020_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00296-007-0489-0","article-title":"Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid","volume":"28","author":"Parker","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2025.12.020_bib22","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib23","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jid.2017.05.035","article-title":"Cannabinoid reduces inflammatory cytokines, tumor necrosis factor-\u03b1, and Type I interferons in dermatomyositis in vitro","volume":"137","author":"Robinson","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.jid.2025.12.020_bib25","first-page":"574","article-title":"Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes","volume":"26","author":"Selvi","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2025.12.020_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jid.2025.12.020_bib27","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ibd.20960","article-title":"Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis","volume":"15","author":"Storr","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2025.12.020_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2015.07.010","article-title":"Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis","volume":"99","author":"Wen","year":"2015","journal-title":"Neuropharmacology"},{"issue":"Suppl. 9","key":"10.1016\/j.jid.2025.12.020_bib29","article-title":"Cutaneous manifestations, clinical trials, safety efficacy and safety of lenabasum in the phase 3 DeterMine trial in dermatomyositis","volume":"74","author":"Werth","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2025.12.020_bib30","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of Lenabasum, a cannabinoid receptor Type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.12.020_bib31","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2025.12.020_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1189\/jlb.0307159","article-title":"Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis","volume":"82","author":"Xu","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jid.2025.12.020_bib33","first-page":"241","article-title":"[Expression of cannabinoid receptor I during mice skin incised wound healing course]","volume":"26","author":"Zhao","year":"2010","journal-title":"Fa Yi Xue Za Zhi"},{"key":"10.1016\/j.jid.2025.12.020_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00414-012-0741-3","article-title":"Cannabinoid receptor type 2 is time-dependently expressed during skin wound healing in mice","volume":"126","author":"Zheng","year":"2012","journal-title":"Int J Legal Med"},{"key":"10.1016\/j.jid.2025.12.020_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4049\/jimmunol.165.1.373","article-title":"Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway","volume":"165","author":"Zhu","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2025.12.020_bib36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-2952(02)01604-0","article-title":"Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid","volume":"65","author":"Zurier","year":"2003","journal-title":"Biochem Pharmacol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:40:47Z","timestamp":1782477647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0022202X26000072"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.020","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenabasum, a cannabinoid type 2 receptor agonist, exerts anti-inflammatory effects in dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Investigative Dermatology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}